BioHealth Innovation
If you are having trouble viewing this email, please click here

March 19, 2019


Anne Lindblad, Ph.D., President, and CEO of Emmes, joins Rich Bendis for BioTalk

BioTalk Host Rich Bendis sits down with Anne Lindblad, Ph.D., President, and CEO of Emmes, to discuss her view of the region, her history with the company, and their mission, vision, and values.

Anne Lindblad, Ph.D., joined Emmes in 1982 as a Biostatistician and is currently the President and CEO. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry. Dr. Lindblad has been an NIH reviewer on multiple project applications for NINDS, NEI, NICHD, NIDCR, NIDDK, and NCCAM and has served as a member or chair of several Data and Safety Monitoring Committees for NEI, NIAAA, NIDDK, and NINDS. She was a member of an Advisory Committee charged with drafting policy to shape the appropriate planning and conduct of intramural studies at NIH. She was elected to the Board of Directors for the Society for Clinical Trials (2003-2006) and served as Program Chair (2002), as an Officer (2006-2014), and as President (2012-2013). Dr. Lindblad was selected to serve on NIH’s National Advisory Dental and Craniofacial Research Council from 2004 through 2008. She has taught courses in best practices in clinical trial design and conduct for ophthalmologists, neurologists, and immunologists. She has published and presented over 100 manuscripts in peer-reviewed journals and conferences. Dr. Lindblad joined the Board of BioHealth Innovation in 2018.  Emmes has grown from 15 employees in 1982 to over 650 globally. In 2019 Emmes announced a significant investment by Behrman Capital which will allow Emmes to gain access to new tools, talent, service offerings, and expanded footprint faster than what Emmes might otherwise have accomplished.

Listen now on iTunesGoogle Play, and TuneIn

Read More

2019 Fifth Annual BioHealth Capital Region Forum...Great Speakers and Networking...Register Today!

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.


Register at

For more information about our speakers and event schedule, please visit

Read More

Osiris to be acquired by British medical device company for $660.5M - Baltimore Business Journal

Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud.

Read More

We’re not doing enough for our kids | Kurt Newman | TEDxTysons - YouTube

It all begins at birth. That’s the starting point for Kurt Newman as he shares his poignant journey as a pediatric surgeon. Newman offers a new perspective for approaching the most chronic and debilitating health conditions. Against a backdrop of personal challenges and patients who overcame impossible odds, we learn to appreciate the importance of treating every child with early customized care, and an eye for the future.

Read More

Built For Bio: Greg Merril, CEO of Adaptive Phage Therapeutics — MCEDC

MCEDC discovers how Greg’s clinical-stage company in Montgomery County, MD is using bacteria phage to combat the worldwide crisis in multi-drug resistant bacterial infections.

Read More

New Study Shows Bayh-Dole is Working as Intended

Just as the drug pricing debate on Capitol Hill is heating up, an important new study, “The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System,” published by the Information Technology & Innovation Foundation (ITIF), underscores the law’s contribution to the United States’ lead in the life sciences. The report warns that attempts to misuse the march-in rights provision of the law to control drug prices would have serious consequences to our competitiveness and our health.

Read More

Successful Marketing & PR Strategies for Your Startup (4/4)
  • PR and Marketing – What’s the difference?
  • How do you establish your brand?
  • Are their tips for marketing on a tight budget?
  • What should an effective marketing plan include?
  • How can a strong digital strategy build credibility?
  • How can I get press coverage for my product/service/technology?
  • What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee8:30 a.m.  – Issues Overview and Discussion (in person/by videoconference)

  • Pam Clark, Principal, Creative Director - Clark Concepts
  • Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
  • Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
  • Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.  

To register/for more information, email:  BHI@BioHealthInnovation.   (Please include in your RSVP:  Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

Read More

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time · BioBuzz

In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological term—that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one. This process of Creative Destruction is the essential fact about capitalism.”

Read More

The Universities at Shady Grove April 6 Expo Targets Potential Undergraduates | Montgomery Community Media

The Universities at Shady Grove (USG) will hold a Undergraduate Expo Saturday, Apr. 6 from 9 a.m. to noon. USG is part of the University System of Maryland and offers approximately 80 undergraduate and graduate degree programs from nine different state universities on the Rockville campus.

Read More

Alexandria Real Estate Equities, Inc. Announces Pricing of Public Offering of $200,000,000 of Senior Notes due 2024, $350,000,000 of Senior Notes due 2026 and $300,000,000 of Senior Notes due 2049

Alexandria Real Estate Equities, Inc. ("Alexandria" or the "Company") (NYSE: ARE) today announced that it has priced a public offering of $200,000,000 aggregate principal amount of 4.000% senior notes due 2024, $350,000,000 aggregate principal amount of 3.800% senior notes due 2026 and $300,000,000 aggregate principal amount of 4.850% senior notes due 2049. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers in connection with the public offering and Barclays Capital Inc., BB&T Capital Markets, a division of BB&T Securities, LLC, BBVA Securities Inc., BNP Paribas Securities Corp., Capital One Securities, Inc., Evercore Group L.L.C., Fifth Third Securities, Inc., Mizuho Securities USA LLC, PNC Capital Markets LLC, RBC Capital Markets, LLC, Regions Securities LLC, Samuel A. Ramirez & Company, Inc., Scotia Capital (USA) Inc., SunTrust Robinson Humphrey, Inc., TD Securities (USA) LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC are acting as co‑managers in connection with the public offering.

Read More

Personal Genome Diagnostics CE Marks Liquid Biopsy Test | BioSpace

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to PGDx elio™ plasma resolve. It is the first kitted plasma-based NGS oncology test to have that certification, enabling greater access to genomic testing for cancer patients in Europe.

Read More

Sonavex readies to launch sales of medical tech with new FDA clearance - Baltimore Business Journal

Sonavex is first targeting the reconstructive surgery market with its new medical technology, which just earned its final FDA clearance.

Read More

LifeBridge Health and CareFirst are hosting an 'innovation challenge' for digital health startups - Baltimore

A pair of Baltimore healthcare leaders are partnering to reach digital health startups.

Hospital network LifeBridge Health and health insurance provider CareFirst BlueCross Blue Shield will be hosting an innovation challenge that includes a chance to pitch and win funding for companies.

Read More

Biopharma breathes 'sigh of relief' with HHS' interim FDA appointment: analyst | FiercePharma

It didn’t take long for the Trump administration to tap Ned Sharpless, now director of the National Cancer Institute, to take the reins at FDA for now—or for biopharma to hail the news. In fact, one team of analysts said the industry would “breathe a collective sigh of relief.”

Read More

How Eargo Is Destigmatizing Hearing Loss Through Innovation

Eargo, a direct-to-consumer health technology company that is destigmatizing hearing loss through innovation, announced it raised $52 million in Series D funding from existing investors New Enterprise Associates (NEA), the Charles and Helen Schwab Foundation, Nan Fung Life Sciences, and Maveron. And new investor Future Fund also participated in this round.

Read More

Amazon's joint health-care venture finally has a name: Haven

The joint health-care venture between Amazon AMZN , J.P. Morgan JPM and Berkshire Hathaway BRK.A finally has a name: "Haven."

Read More

Top 15 Best-Selling Drugs of 2018

For American patients aching for relief from the sky-high price of drugs, the news has been decidedly mixed recently.

Read More

Study: Memories of music cannot be lost to Alzheimer's and dementia

The part of your brain responsible for ASMR catalogs music, and appears to be a stronghold against Alzheimer's and dementia.

Read More

Houston scientist wins Nobel Prize for breakthrough cancer treatment - CultureMap Houston

The already much-heralded University of Texas MD Anderson Cancer Center has just scored global bragging rights. James Allison, Ph.D., a scientist at MD Anderson Cancer Center, has been awarded the 2018 Nobel Prize in Physiology or Medicine, it was announced on October 1.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.